Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
MediWound
(NASDAQ:MDWD)
Intraday
$17.47
-0.12
[-0.68%]
After-Hours
$17.47
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$17.47
-0.12
[-0.68%]
At close: Apr 24
$17.47
0
[0.00%]
After Hours: 6:39PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for MediWound Stock (NASDAQ:MDWD)
MediWound Stock (NASDAQ: MDWD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 22, 2024
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
Benzinga Newsdesk
-
Mar 22, 2024, 6:18AM
Thursday, March 21, 2024
MediWound Q4 EPS $(0.19) Beats $(0.23) Estimate, Sales $5.34M Beat $5.32M Estimate
Benzinga Newsdesk
-
Mar 21, 2024, 7:04AM
Earnings Scheduled For March 21, 2024
Benzinga Insights
-
Mar 21, 2024, 6:15AM
Wednesday, March 20, 2024
Preview: MediWound's Earnings
Benzinga Insights
-
Mar 20, 2024, 1:01PM
Monday, February 12, 2024
MediWound Announced The Results Of Head-To-Head Comparison Analyses Of EscharEx To Collagenase SANTYL Ointment, Approved By The FDA For Debriding Chronic Dermal Ulcers
Benzinga Newsdesk
-
Feb 12, 2024, 7:04AM
Tuesday, January 16, 2024
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $28
Benzinga Newsdesk
-
Jan 16, 2024, 7:27AM
Tuesday, January 09, 2024
MediWound Says FDA Accepted For Review The Supplement To The NexoBrid BLA To Include Pediatric Patients With Severe Thermal Burns
Benzinga Newsdesk
-
Jan 9, 2024, 7:03AM
Thursday, December 28, 2023
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Shivani Kumaresan
-
Dec 28, 2023, 11:54AM
MediWound Disclosed That The US Department Of Defense Awarded An Additional $6.7M In Non-dilutive Funding To Develop NexoBrid As A Non-surgical Solution For Field-care Burn Treatment For The US Arm
Benzinga Newsdesk
-
Dec 28, 2023, 7:04AM
Thursday, December 21, 2023
MediWound Announces Peer-Reviewed Publication Of EscharEx Mechanism Of Action Study Assessing Its Effects On Biofilm And Microbial Loads
Benzinga Newsdesk
-
Dec 21, 2023, 8:13AM
Wednesday, November 22, 2023
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $26 Price Target
Benzinga Newsdesk
-
Nov 22, 2023, 6:35AM
Tuesday, November 21, 2023
Earnings Scheduled For November 21, 2023
Benzinga Insights
-
Nov 21, 2023, 7:12AM
Recap: MediWound Q3 Earnings
Benzinga Insights
-
Nov 21, 2023, 7:10AM
MediWound Q3 EPS $(0.24) Beats $(0.44) Estimate, Sales $4.78M Beat $4.74M Estimate
Benzinga Newsdesk
-
Nov 21, 2023, 7:05AM
Monday, November 20, 2023
Earnings Outlook For MediWound
Benzinga Insights
-
Nov 20, 2023, 10:01AM
Wednesday, November 08, 2023
MediWound Announces A Collaboration With PolyMedics Innovations (PMI) for NexoBrid Distribution In Europe
Benzinga Newsdesk
-
Nov 8, 2023, 7:16AM
Monday, October 09, 2023
MediWound Addresses Emergency Demand For NexoBrid To Treat The Mass Of Burn Casualties, Inflicted By The War In Israel
Benzinga Newsdesk
-
Oct 9, 2023, 7:37AM
Thursday, September 21, 2023
HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know
Benzinga Insights
-
Sep 21, 2023, 1:00PM
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $26
Benzinga Newsdesk
-
Sep 21, 2023, 8:24AM
MediWound Reports US Commercial Availability Of NexoBrid For Treatment Of Severe Thermal Burns In Adults
Benzinga Newsdesk
-
Sep 21, 2023, 6:02AM
Friday, September 08, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 8, 2023, 1:58PM
Thursday, September 07, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Sep 7, 2023, 1:55PM
Wednesday, September 06, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 6, 2023, 2:43PM
Thursday, August 17, 2023
What 4 Analyst Ratings Have To Say About MediWound
Benzinga Insights
-
Aug 17, 2023, 11:00AM
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $36
Benzinga Newsdesk
-
Aug 17, 2023, 8:02AM
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $23 Price Target
Benzinga Newsdesk
-
Aug 17, 2023, 6:22AM
Tuesday, August 15, 2023
MediWound Q2 EPS $0.10 Beats $(0.41) Estimate, Sales $4.77M Beat $4.19M Estimate
Happy Mohamed
-
Aug 15, 2023, 4:11PM
MediWound Announces Collaboration With MIMEDX On EscharEx Phase III Study
Happy Mohamed
-
Aug 15, 2023, 4:09PM
MediWound Announces Collaboration With Mölnlycke On EscharEx Phase III Study
Happy Mohamed
-
Aug 15, 2023, 4:08PM
Earnings Scheduled For August 15, 2023
Benzinga Insights
-
Aug 15, 2023, 4:02AM
Monday, August 14, 2023
Earnings Outlook For MediWound
Benzinga Insights
-
Aug 14, 2023, 12:01PM
Wednesday, August 02, 2023
MediWound Said Partner Vericel Has Received The First Lot Of Nexobrid Finished Product From Mediwound For The U.S. Commercial Market In June 2023
Charles Gross
-
Aug 2, 2023, 8:04AM
Monday, July 17, 2023
MediWound Ltd. Signed A Scale-Up Agreement With Biopharmax Group Ltd. To Establish A State-Of-The-Art Manufacturing Facility And Increase Production Capacity To Meet The Growing Global Demand For Nexobrid; Estimated $12M Will Be Invested In The Project
Happy Mohamed
-
Jul 17, 2023, 4:05PM
Wednesday, May 31, 2023
Oppenheimer Reiterates Outperform on MediWound, Maintains $63 Price Target
Benzinga Newsdesk
-
May 31, 2023, 7:58AM
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $23 Price Target
Benzinga Newsdesk
-
May 31, 2023, 6:40AM
Tuesday, May 30, 2023
Earnings Scheduled For May 30, 2023
Benzinga Insights
-
May 30, 2023, 8:53AM
Recap: MediWound Q1 Earnings
Benzinga Insights
-
May 30, 2023, 7:15AM
MediWound Says NexoBrid US Launch Expected In Early Q3 Of 2023
Benzinga Newsdesk
-
May 30, 2023, 7:06AM
MediWound Q1 EPS $(0.44) Vs. $(0.87) Prior Year, Sales $3.80M Miss $5.15M Estimate
Benzinga Newsdesk
-
May 30, 2023, 7:03AM
Monday, May 29, 2023
Earnings Outlook For MediWound
Benzinga Insights
-
May 29, 2023, 11:00AM
Friday, March 17, 2023
5 Analysts Have This to Say About MediWound
Benzinga Insights
-
Mar 17, 2023, 2:01PM
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $23 Price Target
Benzinga Newsdesk
-
Mar 17, 2023, 11:29AM
Thursday, March 16, 2023
MediWound Q4 EPS $(1.18) Versus $(1.07) Last Year, Sales $11.62M Beat $6.60M Estimate
Benzinga Newsdesk
-
Mar 16, 2023, 7:12AM
MediWound Appoints Hani Luxenburg As CFO
Benzinga Newsdesk
-
Mar 16, 2023, 7:04AM
Earnings Scheduled For March 16, 2023
Benzinga Insights
-
Mar 16, 2023, 6:59AM
Wednesday, March 15, 2023
Preview: MediWound's Earnings
Benzinga Insights
-
Mar 15, 2023, 12:01PM
Friday, February 03, 2023
MediWound Announces $27.5M Registered Direct Offering Of 1,964,286 Ordinary Shares Priced At-The-Market
Happy Mohamed
-
Feb 3, 2023, 10:32AM
Wednesday, January 04, 2023
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday
Lisa Levin
-
Jan 4, 2023, 7:29AM
HC Wainwright & Co. Maintains Buy on MediWound, Raises Price Target to $23
Benzinga Newsdesk
-
Jan 4, 2023, 4:27AM
Friday, December 30, 2022
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know
Benzinga Insights
-
Dec 30, 2022, 12:01PM
Show more